Skip to content
    RPRX
    Earnings call· Mar 2026(Q1 FY26)

    Royalty Pharma Q1 FY26 earnings call RPRX

    May 6, 2026 Source

    Executive summary

    Royalty Pharma Q1 FY26 — Strong Growth and Strategic Investments

    Royalty Pharma delivered a strong Q1 FY26 with double-digit growth in both portfolio and royalty receipts, driven by its diversified portfolio and strategic capital allocation. The company made significant investments in new royalties and R&D co-funding agreements, while also strengthening its global platform and leadership team. Full-year guidance was raised, reflecting confidence in continued momentum despite some headwinds from LOE and lower milestone receipts.

    Highlights

    5

    • Portfolio receipts grew 10% in Q1 FY26.

    • Royalty receipts, representing recurring cash flows, grew 13% in Q1 FY26.

    • Announced $1.25 billion in transactions across three attractive therapies.

    • Repurchased 1 million shares for $50 million and increased dividend by 7% in the quarter.

    • Revolution Medicines' daraxonrasib showed unprecedented Phase III results in pancreatic cancer, nearly doubling overall survival.

    Concerns

    3

    • Experienced a 3% headwind to royalty receipts due to the loss of exclusivity for Promacta.

    • Expected decrease in milestones and other contractual receipts from $128 million in 2025 to approximately $60 million in 2026.

    • Resolution for the arbitration with Vertex has been pushed out to around mid-2027.

    Guidance & targets

    7
    CategoryTargetConfidence
    Full-year 2026 Portfolio Receipts
    $3.325 billion to $3.45 billion
    high materiality
    High
    Full-year 2026 Royalty Receipts Growth
    around 4% to 8%
    medium materiality
    High
    Full-year 2026 Operating and Professional Costs
    5.5% to 6.5% of portfolio receipts
    low materiality
    High
    Full-year 2026 Interest Paid
    around $350 million to $360 million
    low materiality
    High
    Q2 FY26 Portfolio Receipts
    $740 million and $760 million
    medium materiality
    High
    Vertex Arbitration Resolution
    around the middle of 2027
    medium materiality
    High
    Long-term Portfolio Receipts Target
    meet or exceed $5 billion
    high materiality
    High

    Operational metrics

    23
    Portfolio receipts
    $899 million+10% YoY
    Q1 FY26

    Top-line growth driven by the diversified portfolio.

    Royalty receipts
    $839 million+13% YoY
    Q1 FY26

    Recurring cash flows, key drivers were Tremfya, Voranigo, and Evrysdi.

    Operating and professional costs
    3.9%
    Q1 FY26

    Reflects cash savings from the internalization transaction completed in May.

    Net interest paid
    $167 million
    Q1 FY26

    Reflects semiannual timing of interest payments, primarily in Q1 and Q3.

    Portfolio cash flow (adjusted EBITDA less net interest paid)
    $722 million
    Q1 FY26

    Cash generated by the business for reinvestment.

    Net margin
    around 78%
    Q1 FY26

    Demonstrates high underlying cash conversion and efficiency.

    Capital deployment
    $528 million
    Q1 FY26

    Mainly reflected upfront payments for Ziihera and AVLAYAH, and a milestone payment related to Telly.

    Share repurchases
    $50 million
    Q1 FY26

    Part of capital returned to shareholders.

    Dividend increase
    7%
    Q1 FY26

    Part of capital returned to shareholders.

    Weighted average share count
    declined approximately 4%YoY
    Q1 FY26

    Reflecting the impact of the share buyback program.

    Return on invested capital
    14.1%
    LTM Q1 FY26

    Continuing to invest at attractive returns.

    Return on invested equity
    19.7%
    LTM Q1 FY26

    Shows the impact of conservative leverage on equity returns.

    Cash and equivalents balance
    $586 million
    March 31, 2026

    Maintained financial flexibility.

    Investment-grade debt outstanding
    $9.2 billion
    March 31, 2026

    Part of the company's financial structure.

    Leverage (total debt to adjusted EBITDA)
    2.9x
    March 31, 2026

    Low leverage, providing financial flexibility.

    Leverage (net debt to adjusted EBITDA)
    2.7x
    March 31, 2026

    Low leverage, providing financial flexibility.

    Revolver access
    $1.8 billion
    March 31, 2026

    Part of the company's financial flexibility.

    Total financial flexibility
    approximately $4 billion
    March 31, 2026

    Through cash, business generation, and debt markets access.

    Capital returned to shareholders
    approximately $186 million
    Q1 FY26

    Includes share repurchases and dividends.

    Interest received on cash balance
    $6 million
    Q1 FY26

    Not included in interest paid guidance.

    Milestones and other contractual receipts
    approximately $60 milliondown from $128 million in 2025
    FY26

    Expected decrease year-over-year.

    R&D spend by Global Biopharma
    over $1 trillioncumulative projected
    next 5 years

    Represents a major market opportunity for R&D co-funding.

    Capital deployment capacity
    something like $30 billion
    long-term

    The business has the capacity to invest a huge amount of money, with $12 billion guided for annual deployment and additional capacity for opportunistic investments.

    Industry KPIs

    7
    MetricValueDetails
    Peak sales guidance—
    Pricing policy impact—
    Product franchise net sales—
    Geographic regional revenue growth—
    Clinical trial efficacy safety data—
    Patent expiry loe biosimilar erosion—
    Business development capacity deal size appetiteup to $30 billionUSD

    Deals & partnerships

    5
    Zymeworksroyalty acquisition$250 million upfront

    Acquired 30% of Zymeworks' royalty on Jazz's Ziihera, an FDA-approved HER2-targeted bispecific antibody for metastatic biliary tract cancer, recently submitted for approval in gastric cancer.

    TevaR&D co-funding agreementup to $1 billion (combined with J&J deal)

    R&D co-funding agreement for a therapy, part of a $1 billion total announced value with J&J.

    Johnson & JohnsonR&D co-funding agreementup to $1 billion (combined with Teva deal)

    R&D co-funding agreement for their autoimmune therapy 4804, part of a $1 billion total announced value with Teva.

    Revolution Medicineslong-term funding agreement (synthetic royalty)up to $2 billion

    Agreement to provide funding for the clinical development and commercialization of daraxonrasib. Future tranches are at the option of Revolution Medicines.

    MLX (acquired by Teva)royalty entitlementup to $900 million (acquisition price)

    Teva announced the acquisition of MLX, which entitles Royalty Pharma to royalties on Emalex's ecopipam for Tourette's.

    Risks & headwinds

    6
    Loss of exclusivity for PromactaQ1 FY26

    3% headwind to royalty receipts

    Expected decrease in milestones and other contractual receiptsFY26

    from $128 million in 2025 to approximately $60 million in 2026

    Launch of biosimilar TYSABRI in the United StatesFY26

    potential impact on guidance

    Potential impact of Inflation Reduction Act (IRA)FY26

    potential impact on guidance

    Delay in Vertex arbitration resolutionmid-2027

    resolution pushed to mid-2027

    MFN (Most Favored Nation) risk for OUS launches

    uncertainty in pharma launch behaviors and pricing strategies

    Mitigation: Royalty Pharma approaches this by thinking through different scenarios and structuring investments to protect shareholders.

    Q&A highlights

    8

    How much of the $5 billion 2030 portfolio receipts target is de-risked, and how much comes from already commercialized assets?

    Management expressed high confidence in meeting or exceeding the $5 billion 2030 target, citing strong portfolio performance and recent deals, but did not provide a specific breakdown of de-risked vs. commercialized assets.

    “Yes. So Hardik, we feel like we're really on track to meet or exceed that target. The portfolio is doing really well. We've had a lot of positive developments. We've executed some great deals. So we haven't gotten into specifics on that at this point, but I feel like we're very much on track or very confident in meeting or exceeding that long-term guidance.”

    asked by Hardik Parikh (JPMorgan) · answered by Terrance Coyne

    2 min read6 chapters

    Detailed Narrative

    01

    Growing Opportunity in R&D Co-funding

    Royalty Pharma sees a significant opportunity in R&D co-funding with global biopharma, projecting over $1 trillion in cumulative R&D spend by biopharma in the next five years. This modality allows biopharma to share risk, enhance ROI, expand R&D capacity, and diversify pipelines. For Royalty Pharma, it unlocks new market access to high-priority clinical programs and leverages partners' expertise, as evidenced by $1 billion in deals with J&J and Teva in Q1 FY26.

    02

    Strategic Investments and Portfolio Expansion

    The company announced $1.25 billion in transactions during the quarter, deploying over $0.5 billion in capital. Key investments include a royalty on Jazz's Ziihera, an approved cancer therapy with blockbuster potential, and R&D co-funding agreements with Teva and J&J for autoimmune therapy 4804. These deals align with Royalty Pharma's strategy to invest in transformative therapies backed by strong clinical and commercial infrastructure.

    03

    Strengthening Global Platform and Capabilities

    Royalty Pharma is enhancing its global platform, particularly in the Asia Pacific region and artificial intelligence. New leaders like Greg Ops, Ken Sen (Head of Asia), and Lucas Glass (Head of AI) have been brought in to support long-term growth and strengthen competitive advantages. Chris Hite's new role as Chairman, Partnering and Investments, will further expand global relationship networks and play a central role in transactions.

    04

    Pipeline Progress and Future Catalysts

    The development-stage pipeline continues to deliver, with positive Phase III results for Revolution Medicines' daraxonrasib in pancreatic cancer, showing a near doubling of overall survival. Other highlights include FDA approval of Denali AVLAYAH and positive top-line results for MYQORZO in non-obstructive hypertrophic cardiomyopathy. Multiple pivotal readouts are anticipated in 2026 and 2027, including for Novartis' pelacarsen and Sanofi's frexalimab, expected to drive new royalty-generating launches.

    05

    Leveraging Data and AI for Investment Decisions

    Royalty Pharma emphasizes its significant investment in data, including claims data for 200 million Americans and electronic medical records for 44 million. This data is used for internal investment analysis and to share insights with partners, potentially leading to better transaction terms. The recent hiring of Lucas Glass as Head of AI aims to develop and implement AI capabilities across the business, automating diligence and strengthening investment evaluation.

    06

    Financial Flexibility and Capital Allocation

    The company maintains strong financial flexibility with $586 million in cash and equivalents and access to a $1.8 billion undrawn revolver, totaling approximately $4 billion in financial capacity. Leverage stands at 2.9x total debt to adjusted EBITDA. Royalty Pharma has a long-term capacity to deploy up to $30 billion, with a product-driven approach that includes expanding into new markets like China and increasing R&D co-funding with big pharma.

    AI-generated summary of the company’s earnings call. Not investment advice.